Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR ...Middle East

PR Newswire - News
STOCKHOLM, March 17, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that data from the company's leading program fostroxacitabine bralpamide...

Hence then, the article about medivir to present data on additive efficacy of fostrox in triple combination with anti pd1 and kinase inhibitor in nonclinical tumor models at aacr was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News